Stabilized polypeptide compositions

Details Stabilized polypeptide compositions Stabilized polypeptide compositions

2011-06-14

2011-06-14

Huynh, Phuong (Department: 1644)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Recombinant dna technique included in method of making a...

C435S252300, C435S326000, C536S023530, C530S387100, C530S387300, C530S388220

Reexamination Certificate

active

07960142

ABSTRACT:
The invention is based, at least in part, on the development of stabilized binding molecules that consist of or comprise a stabilized scFv and methods for making such stabilized molecules.

REFERENCES:
patent: 5637481 (1997-06-01), Ledbetter et al.
patent: 5747654 (1998-05-01), Pastan et al.
patent: 5854027 (1998-12-01), Steipe et al.
patent: 5917021 (1999-06-01), Lee
patent: 5958784 (1999-09-01), Benner et al.
patent: 5990275 (1999-11-01), Whitlow et al.
patent: 6132992 (2000-10-01), Ledbetter et al.
patent: 6147203 (2000-11-01), Pastan et al.
patent: 6262238 (2001-07-01), Steipe et al.
patent: 6377893 (2002-04-01), Benner
patent: 6482919 (2002-11-01), Ledbetter et al.
patent: 6558672 (2003-05-01), Pastan et al.
patent: 7799902 (2010-09-01), Browning et al.
patent: 2002/0012989 (2002-01-01), Ledbetter et al.
patent: 2003/0219876 (2003-11-01), Ledbetter et al.
patent: 2005/0038609 (2005-02-01), Benner
patent: 2005/0163782 (2005-07-01), Glaser et al.
patent: 2008/0050370 (2008-02-01), Glaser et al.
patent: 2009/0130105 (2009-05-01), Glaser et al.
patent: 2009/0155255 (2009-06-01), Glaser et al.
patent: 2009/0162380 (2009-06-01), Glaser et al.
patent: 0610046 (2005-12-01), None
patent: WO-88/01649 (1988-03-01), None
patent: WO-93/11161 (1993-06-01), None
patent: WO-96/02574 (1996-02-01), None
patent: WO 98/41641 (1998-09-01), None
patent: WO 03/025018 (2003-03-01), None
patent: WO-03/075129 (2003-09-01), None
patent: WO 2004/058191 (2004-07-01), None
patent: WO 2005/121177 (2005-12-01), None
Young et al, FEBS Letters 377: 135-39, 1995.
Young, N. M. et al. “Thermal stabilization of a single-chain Fv antibody fragment by introduction of a disulphide bond,” FEBS Letters, vol. 377:135-139 (1995).
Altschuh, D. et al., “Modulation of the enzymatic activity of papain by interdomain residues remote from the active site,”Protein Enginering, vol. 7(6):769-775 (1994).
Altschuh, T. et al., “Coordinated amino acid changes in homologous protein families,”Protein Engineering, vol. 2(3):190-199 (1998).
Altshuh, D. et al., “Correlation of Co-ordinated Amino Acid Substitutions with Function in Viruses Related to Tobacco Mosaic Virus,”J. Mol. Biol., vol. 193:693-707 (1987).
Arndt, M.A. et al., “Generation of a highly stable, internalizing anti-CD22 single-chain Fv fragment for targeting non-Hodgkin's lymphoma,”International Journal of Cancer, vol. 107:822-9 (2003).
Bera, Tapan K. et al., “Bivalent Disulfide-stabilized Fragment Variable Immunotoxin Directed against Mesotheliomas and Ovarian Cancer,”Molecular Cancer Therapeutics, vol. 1:79-84 (2001).
Chatellier, Jean et al., “Functional Mapping of Conserved Residues Located at the VL and VH Domain Interface of a Fab,”J. Mol. Biol., vol. 264:1-6 (1996).
Chelvanayagam, Gareth et al., “An analysis of simultaneous variation in protein structures,”Protein Engineering, vol. 10(4):307-316 (1997).
Choulier, Laurence et al., “Covariance analysis of protein families: The case of the variable domains of antibodies,”PROTEINS: Structure, Function, and Genetics, vol. 41:475-484 (2002).
Choulier, Laurence et al., “Kinetic Analysis of the Effect on Fab Binding of Identical Substitutions in a Peptide and Its Parent Protein,”Biochemistry, vol. 38:3530-3537 (1999).
Coloma, M.J. et al., “Design and production of novel tetravalent bispecific antibodies,”Nature Biotechnology, vol. 15(2):159-63 (1997).
Davidson, Alan, “Multiple Sequence Alignment as a Guideline for Protein Engineering Strategies,”Methods in Molecular Biology, vol. 340:171-181 (2006).
Demarest, S.J. et al., “Engineering stability into theEscherichia colisecreted Fabs leads to increased functional expression,”Protein Engng. Des. Select, vol. 19(7):325-36 (2006).
Demarest, S.J. et al., Optimization of the antibody CH3 domain using residue frequency analysis of IgG sequences.J. Mol. Biol., vol. 335:41-48 (2004).
Desplancq, D. et al., “Multimerization behaviour of single chain Fv variants for the tumour-binding antibody B72.3,”Protein Engineering, vol. 7(8):1027-33, 1994.
Ewert, S. et al., “Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering,”Methods., vol. 34:184-199 (2004).
Göbel, Ulrike et al., “Correlated Mutations and Residue Contacts in Proteins,”Proteins: Structure, Function, and Genetics, vol. 18:309-317 (1994).
Govindarajan, Sridhar et al., “Systematic Variation of Amino Acid Substitutes for Stringent Assessment of Pairwise Covariation,”J. Mol. Biol., vol. 328:1061-1069 (2003).
Hugo, N. et al., “VL position 34 is a key determinant for the engineering of the stable antibodies with fast dissociation rates,” Protein Engineering, vol. 16(5):381-386 (2003).
Hugo, Nicolas et al., “Functional aspects of co-variant surface charges in an antibody fragment,”Protein Science, vol. 11:2697-2705 (2002).
Khalifa, Myriam Ben et al., “Effects on interaction kinetics of mutations at the VH-VL interface of Fabs depend on the structural context,”Journal of Molecular Recognition, vol. 13:127-139 (2000).
Knappik, A. et al., “Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides,”J Mol. Biol., vol. 296: 57-86 (2000).
Krishnadev, O. et al., “PRODOC: a resource for the comparison of tethered protein domain architectures with in-built information on remotely related domain families,”Nucleic Acids Research, vol. 33:W126-W129 (2005).
Larson, Stefan M. et al., “Analysis of Covariation in an SH3 Domain Sequence Alignment: Applications in Tertiary Contact Prediction and Design of Compensating Hydrophobic Core Substitutions,”J. Mol. Biol., vol. 303:433-446 (2000).
Liu, Yanshun et al., “3D domain swapping: As domains continue to swap,”Protein Science, vol. 11:1285-1299 (2002).
Magliery, Thomas J. et al., “Beyond Consensus: Stastical Free Energies Reveal Hidden Interactions in the Design of a TPR Motif,”J. Mol. Biol., vol. 343,731-745 (2004).
Nellis, David F. et al., “Preclinical Manufacture of an Anti-HER2 scFv-PEG-DSPE, Liposome-Inserting Conjugate. 1. Gram-Scale Production and Purification,”Biotechnol. Prog., vol. 21:205-220 (2005).
Nellis, David F. et al., “Preclinical Manufacture of Anti-HER2 Liposome-Inserting, scFv-PEG-Lipid Conjugate. 2. Conjugate Micelle Identity, Purity, Stability, and Potency Analysis,”Biotechnol. Prog., vol. 21:221-232 (2005).
Nikolova, Penka V. et al., “Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability,”Proc. Natl. Acad. Sci.USA, vol. 95:14675-14680 (1998).
Ortiz, Angel R. et al., “Ab Initio Folding of Proteins Using Restraints Derived From Evolutionary Information,”PROTEINS: Structure, Function, and Genetics Suppl., vol. 3:177-185 (1999).
Pollack, David D. et al., “Coevolving Protein Residues: Maximum Likelihood Identification and Relationship to Structure,”J. Mol. Biol., vol. 287:187-198 (1999).
Pollock, D.D, et al., “Effectiveness of correlation analysis in identifying protein residues undergoing correlated evolution,”Protein Engineering, vol. 10(6):647-657 (1997).
Rauffer, Nathalie et al., “Structure-Activity Relationships for the Interaction Between Cyclosporin A Derivatives and the Fab Fragment of a Monoclonal Antibody,”Molecular Immunology, vol. 31(12):913-922 (1994).
Rauffer-Bruyere, Nathalie et al., “Cooperative Effects of Mutations in a Recombinant Fab on the Kinetics of Antigen Binding,”Molecular Immunology, vol. 34(2):165-173 (1997).
Reiter, Yoram et al., “Engineering antibody Fv fragments for cancer detection and therapy: Disulfide-stabilized Fv fragments,”Nature Biotechnology, vol. 1

Affiliated with

Also associated with

Rating

Stabilized polypeptide compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Stabilized polypeptide compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stabilized polypeptide compositions will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2665872